EUs Critical Dependence on China in Five Key Industrial Sectors Raises Supply Chain Concerns Earnings Calendar Highlights for the Week of May 2529 KLA Corporation KLAC Receives Price Target Hike After Strong Quarterly Results Highlighted as LongTerm Pick Morrisons Plans to Close 100 Stores Citing Government PolicyDriven Cost Pressures US Payrolls Beat Expectations in April but Underlying Weaknesses Raise Concerns Roth Capital Raises Target Price Target but Warns Q1 May Have Been a Goldilocks Quarter MSDL Q1 2026 Earnings Small EPS Beat Meets Modest Market Pullback OHI Q1 2026 Earnings Strong EPS Surprise Amidst Flat Revenue Disclosure and Slight Stock Decline CXT Q1 2026 Earnings EPS Beats Estimates Shares Rally GOOGL Q1 2026 Earnings EPS Misses Estimates as Revenue Uncertainty Weighs on Sentiment GeneDx Holdings Q1 2026 Earnings Significant EPS Miss Shares Decline SRL Q4 2009 Earnings Massive EPS Beat Amidst Unusual Reporting First Mid Bancshares FMBH Holds Steady Near Support Amid Consolidation Hyliion Holdings Corp HYLN Surges 5 Testing Key Resistance at 728 A Paradise Acquisition Corp APAD Holds Steady at 803 in Tight Range Xsolla SPAC 1 Units XSLLU Holds Steady at 998 Amid Consolidation Nuwellis Inc NUWE Pushes Past Key Support Tests Resistance at 110 Nike Stock Rebound Prospects Remain Uncertain Amid Ongoing Challenges CECO Environmental Corp Q1 2026 Earnings Massive EPS Beat of 1395 Surprise North European Oil Royalty Trust NRT Holds Steady Near Support Despite Modest Gains CPSH Q1 2026 Earnings EPS Misses Estimates Stock Rises Over 28 SGML Q1 2026 Earnings EPS Surprises to the Upside Despite Lithium Market Pressures EVGN Q1 2026 Earnings EPS Misses Estimates as PreRevenue Biotech Continues RD Spend DuPont de Nemours Inc DD Q1 2026 Earnings EPS Surpasses Expectations by Double Digits MDLZ Q1 2026 Earnings EPS Beats Estimates by 81 as Snacking Giant Navigates Cost Pressures SVRA Q1 2026 Earnings Wider Loss Amid Continued Pipeline Development SELLAS Life Sciences Group SLS Q1 2026 Earnings WiderthanExpected Loss as PreRevenue Biotech Focuses on Pipeline Progress